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Abstract
Structural and biochemical studies have revealed the importance of a conserved, mobile domain of RNA Polymerase II (Pol II),
the Trigger Loop (TL), in substrate selection and catalysis. The relative contributions of different residues within the TL to Pol II
function and how Pol II activity defects correlate with gene expression alteration in vivo are unknown. Using Saccharomyces
cerevisiae Pol II as a model, we uncover complex genetic relationships between mutated TL residues by combinatorial analysis
of multiply substituted TL variants. We show that in vitro biochemical activity is highly predictive of in vivo transcription
phenotypes, suggesting direct relationships between phenotypes and Pol II activity. Interestingly, while multiple TL residues
function together to promote proper transcription, individual residues can be separated into distinct functional classes likely
relevant to the TL mechanism. In vivo, Pol II activity defects disrupt regulation of the GTP-sensitive IMD2 gene, explaining
sensitivities to GTP-production inhibitors, but contrasting with commonly cited models for this sensitivity in the literature. Our
data provide support for an existing model whereby Pol II transcriptional activity provides a proxy for direct sensing of NTP
levels in vivo leading to IMD2 activation.Finally, we connect PolII activity to transcriptionstart site selection in vivo, implicating
the Pol II active site and transcription itself as a driver for start site scanning, contravening current models for this process.
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Introduction
Cellular DNA-dependent RNA polymerases likely balance
fidelity in substrate selection with synthesis speed to achieve
appropriate transcriptome content and regulation in vivo.I n
multisubunit RNA polymerases (msRNAP) from archaea, bacteria
and eukaryotes, a highly conserved subdomain known as the
trigger loop (TL) is critical for rapid catalysis and selection of
correct substrates [1–9]. The TL is present in the largest subunit of
eukaryotic Pol II, generally referred to as Rpb1 (Rpo21 in
Saccharomyces cerevisiae), and the analogous b9 subunit of bacterial
RNAP, and A0 subunit of archaeal RNAP.
Similarly to mobile domains of other classes of nucleic acid
polymerases, the TL undergoes conformational changes in
conjunction with the presence of an NTP substrate complemen-
tary to the DNA template (matched) in the msRNAP active site
[1,3]. These conformational changes are proposed to link TL-
substrate interactions to preferential catalysis of correctly matched
substrates over mismatched substrates. The TL can be observed in
distinct conformations depending on the presence of matched
NTP substrate, natural product polymerase inhibitors, and
msRNAP-interacting proteins, underscoring its flexibility [1–
3,10–15]. In addition to effects on phosphodiester bond catalysis,
the TL has been implicated in polymerase pausing, intrinsic
cleavage of RNA and translocation [7–9,16,17].
The TL comprises two mostly alpha-helical regions connected
by a short loop (Figure 1A). Deletion or structural compromise of
the TL in either E. coli (Eco)o rT. thermophilus (Tth) strongly
reduces catalytic activity, but to different extents depending on
whether the substrate is matched to the template or not [3–5,7].
Two specific regions of the TL appear important for control of
TL function. First, conserved residues in the nucleotide
interacting region (NIR) recognize specific features of matched
NTP substrates and work in conjunction with non-TL residues,
Rpb1 N479 and R446, positioned for interaction with hydroxyl
moieties on the ribose of matched NTPs [1,3](Figure 1A).
Residues in the NIR showing NTP interactions in S. cerevisiae
and Tth substrate-bound structures are (using S. cerevisiae
Rpb1/Rpo21
Ecob9/Tthb9 numbering) Gln1078
Gln930/Gln1236,L e u -
1081
Met932/Met1238, Asn1082
Arg933/Arg1239 and His1085
His936/His1242.
Second, in all kingdoms of life, substitutions in or near the helix
distal to the NIR alter elongation rate, in some cases increasing
elongation rate relative to WT (‘‘superactivity’’), [2,16,18,19].
These substitutions may alter dynamics of TL movement between
the substrate-interacting conformation and other conformations
because they are adjacent to the hinge region in the C-terminal
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helix)(Figure 1B) [2,9].
NIR residues of the Eco and Tth RNAPs have different degrees
of contribution to catalytic activity, with individual Eco residue
substitutions having smaller effects on activity than homologous
substitutions in Tth, underscoring the diversity of TL residue
functions in msRNAPs [5,7]. A conserved histidine within the TL
NIR has been proposed to have an important or essential catalytic
role [1]. Many classes of structurally distinct nucleic acid
polymerases utilize a basic residue located at a position in the
active site analogous to that of the TL histidine and these residues
function as a general acid in the catalytic cycle of the polymerase
[20]. While clearly important for RNAP catalysis, the TL histidine
appeared not to be functioning as a general acid based on pH-
dependence curves for bacterial RNAPs [5,7]. Experiments in the
different bacterial systems show that a TL methionine residue
(equivalent to S. cerevisiae Leu1081) packs against a base-paired
NTP in the active site and has a greater contribution to activity
than Arg
Eco933/Tth1239 or His
Eco936/Tth1242, which interact with the
triphosphate moiety of matched substrates [5,7].
Genetic identification of mutants with substitutions in the TL
region, first in S. cerevisiae Pol II, then in Eco RNAP, demonstrated
that alteration of the TL could alter transcription in vivo [16,18,21–
23]. How changes in TL function or msRNAP catalysis alter
transcription in vivo are not well understood and to what extent
polymerase activity defects may be tolerated in vivo is not clear. In
S. cerevisiae, drugs that target nucleotide synthesis pathways such as
mycophenolic acid (MPA, targets GTP synthesis) [24] and 6-
azauracil (6-AU, targets UTP and GTP synthesis) [25,26] have
been shown to cause alterations in gene expression in vivo [27–30].
A large number of Pol II transcription-related mutant strains show
altered sensitivities to these drugs, leading to the broadly utilized
interpretation that these drugs are elongation inhibitors and that
sensitivity to them suggests defective Pol II elongation [18,31–54].
Notwithstanding the large number of mutants sensitive to these
drugs that have no known transcriptional role, many MPA-
sensitive mutants alter transcription of the gene IMD2 [35,38,47],
which encodes an MPA-resistant form of IMPDH, the enzymatic
activity targeted by the drug [55,56]. This gene-specific transcrip-
tion defect is not always considered when interpreting mutant
phenotypes. Intriguingly, IMD2 transcription involves a switch
between upstream transcription start sites and downstream
Figure 1. S. cerevisiae Rpb1 trigger loop conformations and sequence. A. Cartoon representation of ‘‘closed’’ Pol II TL in relation to nucleic
acids, Rpb1 bridge helix and a matched GTP substrate from structure PDB 2E2H [1] overlaid with TL constrained in open conformation by TFIIS (not
shown) from structure PDB 1Y1V [69]. Amino acids (all derived from Rpb1) adjacent to the matched GTP substrate are indicated by numbers and
single-letter amino acid codes. This figure was created with Pymol [111]. B. Schematic of TL showing amino acid sequence in single-letter code, with
positions of interest numbered, residues with direct contact to GTP substrate in structure 2E2H shown in green, and position 1103 shown in yellow.
Two hinge regions, about which the TL appears to change conformation from the open to closed positions are indicated.
doi:10.1371/journal.pgen.1002627.g001
Author Summary
Transcription by multisubunit RNA polymerases (msRNAPs)
is essential for all kingdoms of life. A conserved region
within msRNAPs called the trigger loop (TL) is critical for
selection of nucleotide substrates and activity. We present
analysis of the RNA Polymerase II (Pol II) TL from the model
eukaryote Saccharomyces cerevisiae. Our experiments
reveal how TL residues differentially contribute to viability
and transcriptional activity. We find that in vivo growth
phenotypes correlate with severity of transcriptional
defects and that changing Pol II activity to either faster
or slower than wild type causes specific transcription
defects. We identify transcription start site selection as
sensitive to Pol II catalytic activity, proposing that RNA
synthesis (an event downstream of many steps in the
initiation process) contributes to where productive tran-
scription occurs. Pol II transcription activity was excluded
from previous models for selection of productive Pol II
start sites. Finally, drug sensitivity data have been widely
interpreted to indicate that Pol II mutants defective in
elongation properties are sensitized to reduction in GTP
levels (a Pol II substrate). Our data suggest an alternate
explanation, that sensitivity to decreased GTP levels may
be explained in light of Pol II mutant transcriptional start
site defects.
In Vivo Dissection of Pol II Trigger Loop Function
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GTP, downstream: ATP) leading to the proposal that the initiation
process for these different classes of transcript stems from GTP
levels being sensed directly by Pol II [57,58].
The eukaryotic Pol II system provides an excellent model for in
vivo studies of how the TL functions in transcription. Because
nuclear transcription in eukaryotes is segregated among three
essential polymerases instead of one, as in bacteria and archaea,
strong defects may be more tolerated in Pol II than bacterial or
archaeal RNAPs in vivo. We utilized extensive site-directed
mutagenesis of the Pol II TL coupled with genetic screening to
identify viable substitutions in TL NIR residues and substitutions
conferring conditional growth phenotypes. We then used biochem-
ical characterization together with a number of in vivo genetic and
molecular phenotypes to probe the contributions of critical TL
residues to transcription in vivo. We determined the relationship
between NIR residues and superactivating TL substitutions and
found that superactivating substitutions were mostly mutually
suppressive with loss-of-function substitutions within the NIR in
genetic and biochemical assays. These results indicated that NIR
residues were not bypassed by superactivating substitutions and
were still required for Pol II activity. Using a series of TL mutants
that define a continuum of in vitro elongation rates, we demonstrated
that a number of in vivo phenotypes correlated closely with Pol II
activity in vitro. We provide support for models proposing that IMD2
transcription is directly sensitive to Pol II activity, therefore
explaining the MPA-sensitivity of superactive Pol II mutants, which
otherwise might have been expected to be resistant to reduced GTP
levels due to increased elongation activity. Finally, we determined
that start site selection at a number of other genes was similarly
sensitive to alteration in Pol II activity leading to a new model for
transcription-dependent polarity of start site selection in S. cerevisiae.
Results
Genetic Analyses of Rpb1 TL Mutants In Vivo
We have undertaken an extensive genetic dissection of the Pol II
TL: specifically, we examined the contribution of TL residues to
Pol II function, and how Pol II catalytic activity relates to
transcription in vitro and in vivo. To examine a large number of Pol
II mutants in vivo, we employed a yeast strain containing a deletion
of the endogenous copy of RPO21 (the gene encoding Rpb1, which
we henceforth refer to as RPB1) with RPB1 activity complemented
by a low copy CEN plasmid containing RPB1 genomic DNA or
mutant variants, allowing expression from the native RPB1
promoter. Site-directed mutagenesis was focused on TL NIR
residues to identify viable substitutions and was combined with
existing rpb1 TL alleles identified in genetic screens (Text S1,
genetic screens to be described elsewhere). For any viable mutants,
alteration in transcription in vivo was measured with two
phenotypic reporters for transcriptional defects, the lys2-128h
[59] and gal10D56 alleles [60,61](Figure S1). These reporters are
modulated by a number of transcription elongation factors and Pol
II mutants with known transcription defects [2,60,62–66].
Previous analyses indicated that some TL substitutions cause
increases in Pol II elongation rate in vitro (‘‘superactivity’’ or gain of
function(GOF))(e.g. E1103G)[2,9,18]; someofthese increasesin rates
for misincorporation were greater than in rates for incorporation of
templated NTPs, indicating possible loss of fidelity (F1084I, E1103G)
[2,9]. Other substitutions confer reduced elongation rate (loss of
function (LOF))(H1085Y, F1086S) [2]. In vitro activity appeared to
correlate with in vivo phenotypes for the few mutants examined [2].
Suppression of a growth defect on media lacking lysine conferred by
lys2-128h (the Spt
2 phenotype) was observed for known TL GOF
alleles and neighboring substitutions [2]. Lysine auxotrophy of lys2-
128h relates to defective LYS2 transcription caused by a retro-
transposon insertion in LYS2 [59]. Someof these GOF alleles are also
sensitive to MPA or 6-AU, while the Spt
2 phenotype and strong
MPA sensitivity have not been observed among known TL LOF
alleles [2,18]. Both known LOF and GOF alleles confer alteration of
growth phenotypes relating to transcriptional interference at the
GAL10-GAL7 locus when polyadenylation and termination at GAL10
are compromised in the gal10D56 allele [2].
In our current study, we found that the Spt
2 phenotype was
concentrated in residue substitutions proximal to the two TL
‘‘hinges’’ (Figure 2A, 2E, see Figure 1B for positions of hinges).
Growth defects were conferred by substitutions throughout the TL
(Figure 2A, 2B). We found that MPA-sensitivity (MPA
s) and Spt
2
phenotypes generally co-occurred although the relative strength of
the two phenotypes varied among mutants (Figure 2A, 2D, 2E).
Finally, we found that the strongest suppressors of gal10D56, with
the exception of G1097D, were in TL NIR residues and were
mostly Spt
+ or MPA-resistant (MPA
r), indicating a distinction
between these phenotypes (Figure 2C). Taken together, these
conditional plate phenotypes behave as sensitive readouts for likely
complex sets of overlapping or distinct transcriptional defects in vivo.
In Vitro Transcription Elongation Rates Correlate with In
Vivo Growth Defects and Plate Phenotypes
As TL substitutions causing the Spt
2 phenotype included those
with known TL GOF phenotypes (F1084I, E1103G) [2], we asked
if our plate phenotypes were predictive of biochemical phenotypes.
Analysis of TL substitutions in an in vitro transcription assay using
reconstituted Pol II elongation complexes indicated a good
correlation between elongation rate defect in vitro and growth
defect in vivo (Figure 3, Figures S4 and S5). We note that we did
not detect strong expression differences for tested mutant Rpb1
proteins (Figure S6). We previously showed that LOF substitution
H1085Y and a putative GOF substitution (G1097D) caused severe
growth defects in vivo [2]. In this study we find that these two
mutants also represent extremes of Pol II activity defects, but
interestingly at different ends of the activity spectrum. Biochemical
analysis of Spt
2 and MPA
s G1097D and L1101S shows that they
are GOF substitutions conferring increased maximal elongation
rate in vitro. In fact, G1097D elongates too quickly for accurate
measurement in our short template run off assay (Figure 3)(Figures
S4 and S5). We evaluated a number of other TL substitutions and
found that WT elongation rate in vitro correlates with robust
growth in vivo, and that the greater the deviation from WT for
elongation rate in vitro, the greater the deviation from WT growth
in vivo (Figure 3, right panel). We note that the non-TL LOF
substitution, N479S, deviates slightly from this relationship as it
has the most severe in vitro defect but has a less severe growth
defect. This could be consistent with a factor(s) functioning in vivo
that can compensate for the biochemical defect caused by the
N479S substitution but not the H1085Y substitution; for example,
a hypothetical factor that may work through the TL.
Role of E1103-T1095 Interactions in Superactivation of
E1103G
For msRNAPs from each kingdom of life, GOF substitutions
have beenreported inTLresiduesdistaltotheNIRandproximalto
the C-terminal ‘‘hinge’’ region [2,9,16,18,19], which is the portion
of the TL that changes conformation from open to the closed NTP-
interacting orientation (Figure 1). There is evidence that the Pol II
GOF substitution E1103G promotes a closed TL state [9]. An
increased frequency or duration of this state could have conse-
In Vivo Dissection of Pol II Trigger Loop Function
PLoS Genetics | www.plosgenetics.org 3 April 2012 | Volume 8 | Issue 4 | e1002627Figure 2. Genetic analyses of Pol II TL single substitution mutants. A. 10-fold serial dilutions of saturated cultures of Pol II TL mutant strains
plated on different media. YPD is rich medium with dextrose as a carbon source. YPRaf is rich medium with raffinose as a carbon source. YPRaf/Gal
has both raffinose and galactose, allowing assay of gal10D56-dependent galactose toxicity phenotypes. SC-Leu is defined, complete medium lacking
leucine. MPA was added to this medium (SC-Leu+MPA) to 20 mg/ml final concentration, showing that a number of Pol II mutants are sensitive to this
drug. SC-Lys is defined, complete medium lacking lysine, and detects the Spt
2 phenotype (Lys
+) for strains containing lys2-128h. WT strains grow
robustly on most media, but will not grow on SC-Lys when lys2-128h is present and grow very poorly on YPRaf/Gal when gal10D56 is present. Mutant-
dependent transcriptional phenotypes allow modulation of these specific growth defects. B. Schematic of TL (as diagrammed in Figure 1B) showing
distribution of viable substitutions with their growth defects on YPD as well as lethal substitutions. All mutants were examined in the background of
In Vivo Dissection of Pol II Trigger Loop Function
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increase in misincorporation) and translocation (reduced transloca-
tionrate likely due to stabilizationof closed state after catalysis). The
E1103 sidechain interacts with the T1095 sidechain and makes
backbone contacts with K1112 in elongation complex crystal
structures where the TL is in the open conformation or constrained
by other factors [67–69]. Loss of this E1103-T1095 interaction has
been posited to explain the effect of E1103G on Pol II transcription
[9]. We found that the T1095A substitution was phenotypically
indistinguishable from wild type (WT), indicating that loss of
T1095-E1103 contacts are not responsible for E1103G growth
alteration or, most likely, biochemical superactivity (Figure 2).
T1095R, presenting a much longer sidechain that might disrupt
‘‘out conformation’’ hinge folding, only confers weak MPA
s,S p t
2
and Gal
r phenotypes, consistent with C-terminal hinge function or
TL dynamics being controlled more strongly by distal residues or
other contacts of E1103 (Figure S3).
Combinatorial Analyses of TL Substitutions Reveal
Functional Distinctions between Residues with Similar
Single-Mutant Behavior
We next wished to probe genetic relationships between TL
GOF and LOF substitutions, particularly those between TL hinge
residues and TL NIR residues, as these relationships might
provide mechanistic insight into TL function (Figure 4A, Figure
S2, Figure S3, Text S1). Surprisingly, by combining TL GOF with
TL NIR substitutions, we found that either E1103G or G1097D
GOF mutations were able to suppress lethality of many, but not
all, inviable (LOF) single substitution NIR mutants (Figure 4A,
Figure S2, Table 1). Examination of double mutant plate
phenotypes provided more evidence of mutual suppression in
E1103G-NIR mutant combinations because Spt
2 and MPA
s
phenotypes of E1103G were suppressed together with moderate
Gal
r phenotypes of individual NIR substitutions (Figure S2). In
contrast, tested pairwise combinations of genetically and biochem-
ically similar GOF substitutions, F1084I, G1097D and E1103G
resulted in lethality (Figure 4A). Additionally, combination of
viable LOF NIR-residue substitutions with the GOF substitution
E1103G resulted in mutual suppression of conditional plate
phenotypes and growth defects (Figure S2).
If observed plate phenotypes directly relate to elongation rate,
as suggested by our analysis of single substitution mutations
(Figure 3), the observations above predict that the double mutants’
in vitro elongation rates might be closer to WT than those of the
single substitution mutants. We therefore measured elongation
rates of doubly substituted TL mutants to further examine the
an Rpb1 T69 change, which is the allele present in the S288C reference genome as well as being normally found in our strains, representing a
distinction for the subset of mutants described previously [2](see Materials and Methods, Text S1 and note concerning viability of Q1078S). Scoring of
phenotypic strength is based on visual inspection of (A). C. Distribution of gal10D56 suppression (Gal resistance) or enhancement (Gal super-
sensitivity) among TL substitutions. Scoring of phenotypic strength is based on visual inspection of (A). *Indicates strength of gal10D56 suppression is
likely underestimated due to confounding generic growth defects. D. Distribution of MPA phenotypes among TL substitutions. Scoring of phenotypic
strength is based on visual inspection of (A). E. Distribution of lys2-128h suppression (Spt
2 phenotype scored as Lys
+) among TL substitutions.
Scoring of phenotypic strength is based on visual inspection of (A).
doi:10.1371/journal.pgen.1002627.g002
Figure 3. Pol II TL substitution mutants show a wide range of elongation rates in vitro. Pol II TL single substitution elongation rates as
determined in vitro using reconstituted Pol II elongation complexes with synthetic oligonucleotides and an RNA primer (Materials and Methods). Raw
data for some mutants (*) are from [2] and are shown for comparison. Plotted data are maximal elongation rates as determined by non-linear
regression of elongation rates determined for different NTP substrate concentrations, and error bars indicate the range of the 95% confidence
intervals (Figures S4, S5). Growth on rich medium of mutants is shown in the right panels for comparison with elongation defects (from Figure 2).
doi:10.1371/journal.pgen.1002627.g003
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S4 and S5). We found that combination of E1103G and individual
viable LOF substitutions F1086S, H1085Q or H1085Y resulted in
enzymes with activity intermediate between the relevant singly
substituted enzymes. Combination of E1103G individually with
the lethal single substitutions Q1078A, N1082A or H1085A
resulted in viable strains and Pol II enzymes with activity reduced
compared to E1103G alone. The fold enhancement of viable LOF
substitutions F1086S, H1085Q and H1085Y by E1103G was
roughly similar in each case.
Figure 4. Combination of TL substitutions alters in vivo growth and in vitro biochemical phenotypes. A. GOF-GOF and GOF-LOF genetic
interactions among rpb1 TL and other substitutions. GOF (yellow) and LOF (blue) classifications were determined by biochemical and genetic
phenotypes of single substitution mutants, with lethal single substitutions shown in black. Double mutant phenotypes are illustrated as the colored
lines connecting colored nodes of particular single mutants. Schematic of TL sequence and orientation is as in Figure 1B. Data were compiled from
Figure S2, Figure S3 and Table 1. N1082S/F1084I shows a complex interaction with exacerbation of growth defects on rich medium but mutual
suppression of other conditional plate phenotypes. B. In vitro elongation rates determined as in Figure 3 for select Pol II TL double mutant enzymes.
Single mutants and their relevant E1103G double mutants are indicated by color-coding: F1086 and F1086/E1103G, yellow; H1085Q and H1085Q/
E1103G, green; H1085Y and H1085Y/E1103G, blue. Black bars indicate double mutants with E1103G for which the counterpart single substitution
mutant is inviable (Q1078A, N1082A, H1085A). Single mutant data are from Figure 3. Raw data for some mutants (*) are from [2] and are shown for
comparison. Error bars indicate the ranges of the 95% confidence intervals. Note that x-axis is logarithmic scale. Growth on rich medium of mutants is
shown in the right panels for comparison with elongation defects (from Figure 2, Figure S2). C. Interaction diagram showing phenotypes of pairwise
combinations of rpb1 LOF alleles (legend shown in (A)). D. Interaction diagram illustrating genetic interactions between pairs of Rpb1 substitution
mutants each in the presence of the E1103G substitution (yellow shading encompassing all relevant residues, legend shown in (A)).
doi:10.1371/journal.pgen.1002627.g004
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Substitution Phenotype Note
Q1078A Inviable
Q1078N Inviable [2]
Q1078E Inviable
L1081I Inviable
L1081A Inviable
L1081G Inviable
L1081F Inviable
N1082A Inviable
H1085A Inviable [2]
H1085D Inviable
H1085N Inviable
H1085F Inviable [2]
N479S/N1082S Viable Figure S3
N479S/F1084I Viable Figure S3
N479S/H1085Q Inviable Double mutant lethality
N479S/H1085Y Inviable Double mutant lethality
N479S/F1086S Inviable Double mutant lethality
Q1078S/N1082A Viable Q1078S suppresses N1082A lethality, Figure S3
Q1078S/N1082S Viable Figure S3
Q1078S/F1084I Viable Figure S3
Q1078S/H1085Y Inviable Double mutant lethality
Q1078S/H1085Q Inviable Double mutant lethality
Q1078S/H1085A Inviable
Q1078A/N1082A Inviable
N1082S/F1084I Viable Figure S3
N1082S/H1085Y Inviable Double mutant lethality
N1082A/F1084I Viable Figure S3
N1082A/H1085Y Inviable Double mutant lethality
F1084I/H1085Q Viable Figure S3
F1084I/H1085Y Inviable Double mutant lethality
F1084I/E1103G Inviable Double mutant lethality
G1097D/E1103G Inviable Double mutant lethality
N479S/Q1078S/E1103G Viable Figure S3
N479S/N1082A/E1103G Inviable Triple mutant lethality
N479S/H1085A/E1103G Viable Figure S3
N479S/F1084I/E1103G Viable Suppression of F1084I/E1103G lethality, Figure S3
Q1078S/N1082A/E1103G Viable Figure S3
Q1078A/N1082A/E1103G Viable Figure S3
Q1078A/H1085Y/E1103G Inviable Triple mutant lethality
Q1078A/H1085A/E1103G Inviable Triple mutant lethality
Q1078S/H1085A/E1103G Viable Figure S3
N1082S/F1084I/E1103G Viable Figure S3
N1082A/F1084I/E1103G Viable Figure S3
N1082S/H1085Y/E1103G Viable Figure S3
N1082A/H1085Y/E1103G Inviable Triple mutant lethality
N1082A/H1085A/E1103G Inviable Triple mutant lethality
F1084I/H1085Y/E1103G Inviable H1085Y cannot suppress F1084I/E1103G
Q1078S/N1082A/H1085Y/E1103G Viable Figure S3
A1076V/Q1078S/N1082A/H1085Y/E1103G Viable Figure S3
A1076V/Q1078A/N1082A/H1085Y/E1103G Viable Figure S3
In Vivo Dissection of Pol II Trigger Loop Function
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coupled fashion, we constructed pairwise combinations using TL
NIR LOF alleles and a substitution in the TL-adjacent Rpb1
NTP-interacting residue, N479S (Figure 4C). We observed
lethality when H1085 substitutions were combined with substitu-
tions in other TL NIR residues or with N479S, consistent with
H1085 functioning non-redundantly or distinctly from other TL
NIR residues or N479 in the Pol II nucleotide addition cycle.
Surprisingly, when we examined combinations among N479,
Q1078, and N1082 substitutions we did not observe lethality
(Figure 4C). In fact, we observed suppression or epistasis between
Q1078 and N1082 substitutions. These observations suggested a
functional distinction between N-terminal TL NIR residues
(Q1078, N1082) and H1085. Viable substitutions in these residues
maintain sidechains that might still confer some interaction
between the TL and NTPs, however alanine substitutions in key
residues Q1078, N1082, and H1085 were inviable and could not
be directly assessed genetically. Because all LOF TL residues,
including these lethal substitutions, were suppressed by E1103G,
we examined triple mutants that contained pairwise substitutions
in the TL NIR in the background of E1103G (Figure 4D). These
triple mutant combinations revealed similar functional distinctions
between two sets of Pol II active site residues, with the set of
residues containing N479, Q1078 and N1082 being distinct from
H1085. These results may be interpreted in light of structural
information and have implications for the mechanism of TL
function (see Discussion).
In Vivo Transcription Defects of Pol II TL Mutants
To examine our Pol II TL mutants for in vivo transcription
defects, we analyzed expression of IMD genes and URA2
(Figure 5A, 5B), which function in GTP and UTP synthesis,
respectively. Expression of one IMD gene, IMD2, and URA2, have
been linked to GTP or UTP levels, respectively, possibly directly
through alteration of Pol II function by changes in levels of these
transcription substrates [57,58,70,71]. Expression of IMD2 is
required for WT yeast to be resistant to the drug MPA [46,56].
IMD2 transcripts are increased in the presence of MPA due to
reduced GTP levels that result from inhibition of MPA-sensitive
Imd2 homologs, Imd3 and Imd4 [55,56]. A number of
transcription mutants are defective for IMD2 upregulation upon
MPA treatment [35,38,47] while some Pol II mutants have been
reported to show constitutive expression of IMD2 [18,57]. As
IMD2 has a high level of sequence similarity to the pseudogene
IMD1 and to IMD3 and IMD4, and because of possible cross-
hybridization [56], we do not specify that observed changes in our
Northern blotting are solely due to IMD2 changes. However, it has
been demonstrated that the majority of MPA-induced IMD
expression comes from IMD2 [56].
We observed a constitutive upregulation of IMD transcripts in
LOF mutant H1085Y and loss of MPA-responsiveness in GOF
mutants E1103G and G1097D as well as in the H1085Y/E1103G
double mutant (Figure 5A). E1103G appeared to have reduced
expression of IMD genes in the absence of MPA treatment, and
importantly, E1103G and G1097D showed reduced IMD
expression upon MPA treatment. These results are consistent
with the MPA-sensitivity of E1103G and G1097D and the
apparent MPA-resistance of H1085Y (Figure 2) [2]. They also
indicate that defects in IMD expression may fully explain the
MPA-sensitivity of Pol II TL mutants and need not relate to global
elongation defects due to reduced GTP levels, which is the
commonly invoked mechanism for MPA-sensitivity. The results,
however, are consistent with a model in which IMD2 regulation
occurs directly through Pol II-nucleotide sensing.
Activation of URA2 has also been proposed to result from a Pol
II-dependent NTP-sensing event because a class of Pol II mutants
causes constitutive URA2 expression [70,71]. URA2 is normally
controlled by a change in start site selection from upstream start
sites, which produce transcripts that are prematurely terminated
and degraded, to downstream start sites that allow production of
full-length mRNA. The Pol II mutants that lead to URA2
expression are located in the ‘‘switch 1’’ region of Rpb1 [72],
near a residue linked to start site selection [73]. We reasoned that
if URA2 were directly responsive to Pol II-sensing of UTP levels,
then a Pol II TL LOF mutant should also show constitutive
upregulation of URA2, as a reduction of Pol II activity through TL
defects should mimic reduction in substrate levels. We found that
H1085Y caused URA2 to be upregulated (Figure 5B). GOF TL
mutants E1103G and G1097D were closer to WT for URA2
expression, while H1085Y/E1103G showed an increase in URA2
expression. Furthermore, URA2 was not responsive to MPA
treatment, an expected result if URA2 were specifically responsive
to UTP depletion as opposed to GTP depletion.
IMD2, like URA2, is regulated by a shift in start sites from
upstream starts that lead to premature termination, to downstream
starts upon nucleotide limitation [57,58]. The start site changes in
IMD2 are proposed to relate to concentration of initiating NTP,
with upstream starts initiating with GTP, whereas under GTP-
limiting conditions, the major downstream start initiates with ATP
(Figure 5C). We examined this phenomenon in Pol II TL mutants
by primer extension (Figure 5D, 5E). Examination of downstream
start sites at IMD2 showed that the major ATP start site at 2106
from the IMD2 start codon is induced by MPA treatment in WT
cells (Figure 5D) [74]. TL LOF H1085Y showed constitutive
expression from this start regardless of MPA treatment, and,
interestingly, apparent usage of downstream cryptic starts at
approximately 235 and 245. Although mRNA processing in
theory could generate these shorter new transcripts, it is unlikely as
processed transcripts lacking a 59-cap should be fairly unstable. In
contrast, for TL GOF mutants E1103G and G1097D little or no
usage of the 2106 start was observed, regardless of MPA
treatment, consistent with MPA-sensitivity of these strains and
Table 1. Cont.
Substitution Phenotype Note
N1082A/H1085A/G1097D Inviable
DTL Tip (D1077-GG-1087) Inviable Deletion of TL residues 1077–1087, insertion of Gly-Gly linker
DTL Tip/E1103G Inviable E1103G cannot suppress deletion of TL NIR
Abilities of single and multiply substituted Pol II variants to complement the inviability of a deletion of RPO21/RPB1 are illustrated, along with notes on mutant behavior
and relevant figures.
doi:10.1371/journal.pgen.1002627.t001
In Vivo Dissection of Pol II Trigger Loop Function
PLoS Genetics | www.plosgenetics.org 8 April 2012 | Volume 8 | Issue 4 | e1002627Figure 5. Pol II TL mutants alter transcription of IMD2 and URA2, genes required for GTP and UTP synthesis, respectively. A. Northern
blotting for different Pol II mutants in the presence or absence of 20 mg/ml MPA (2 hours treatment) for expression of IMD gene(s) using IMD2 DNA
probe (top). SED1 was probed as a loading control. Values for IMD normalized to the WT ratio of IMD/SED1 are shown in the graph and represent the
mean relative expression for IMD transcript(s) +/2 the standard deviation for at least three independent experiments. B. Northern blotting for URA2
expression in the presence or absence of 20 mg/ml MPA (2 hours treatment) (top). SED1 was probed as a loading control. Values for URA2 normalized
to the WT ratio of URA2/SED1 are shown in the graph and represent the mean relative expression for URA2 +/2 the standard deviation for at least
three independent experiments. C. Schematic of IMD2 gene transcription in the absence or presence of MPA. IMD2 is not functionally expressed in
In Vivo Dissection of Pol II Trigger Loop Function
PLoS Genetics | www.plosgenetics.org 9 April 2012 | Volume 8 | Issue 4 | e1002627Northern blotting showing no MPA induction of IMD transcripts.
In the H1085Y/E1103G mutant that showed mutual suppression
of respective single mutant phenotypes but reduced activity from
WT in vitro, we observed constitutive usage of the 2106 start, but
at apparent lower levels than H1085Y. In addition, we observed
MPA-dependent loss of upstream start site usage in this set of
mutants, suggesting maintained responsiveness to MPA-effects for
these starts, even though H1085Y showed constitutive use of
downstream starts. In contrast to the observed H1085Y usage of
new 235 and 245 downstream start sites (Figure 5D), we
observed increased E1103G and G1097D usage of upstream starts
relative to WT (Figure 5E), suggesting altered start site selection in
Pol II TL mutants.
Activity-Dependent Control of Pol II Start Site Selection In
Vivo
A number of Pol II subunit and general transcription factor
(GTF) mutants have been found to alter start site selection in S.
cerevisiae [73,75–84], but it is unclear how Pol II activity might
relate to these start site defects. For example, deletion of the Rpb9
subunit of Pol II confers many similar activity defects as Pol II TL
GOF substitutions such as increased rate of elongation and
misincorporation [85–87] and is defective for start site switching at
IMD2 in response to MPA [58]. Additionally, rpb9D has long been
known to exhibit upstream shifts in start site selection [77,79,84],
while many mutations throughout Pol II can cause downstream
shifts in start site selection (references above). Models for Pol II
residue function in start site selection have previously focused on
physical or functional interactions between these residues and
GTFs. We propose that the Pol II TL primarily or exclusively
functions in controlling the Pol II nucleotide addition cycle
(substrate selection, catalysis and translocation), which, for this
work, we define as Pol II activity. Therefore we used our TL
mutants to interrogate the relationship between Pol II biochemical
activity and start site selection in vivo, following our observations of
downstream start site usage at IMD2 in TL LOF H1085Y and
apparent upstream shifts in TL GOF E1103G and G1097D
mutants. We examined start site selection at a number of other
genes by primer extension analysis (Figure 6).
We found that TL LOF H1085Y caused downstream shift in
start site distribution at ADH1, similar to reported defects of a
number of other Pol II mutants and GTF mutants (Figure 6A).
In contrast, TL GOF E1103G and G1097D substitutions confer
upstream defects similar to those that occur in rpb9D (references
above), a number of TFIIF mutants [78,80–83], and novel
insertion mutants within TFIIB [88]. As with other in vivo and in
vitro phenotypes, combination of H1085Y and E1103G leads to
mutual suppression, extending the correlation between observed
phenotypes and in vitro activity. For transcripts from HIS4 and
PMA1, genes known to be sensitive to start site alterations in
mutant strains [73,79], we also observed upstream shifts in
E1103G and G1097D-bearing strains (Figure 6B). E1103G-
dependent start site changes were suppressed by H1085Y for
these genes as well. It is not obvious how the alteration of TL
function would impact start site selection so strongly, as we
expect TL function to be downstream of initiation events
important for start site selection, such as pre-initiation complex
formation and promoter melting. The strong upstream starts
observed for GOF mutants led us to predict that these positions
should already be accessible to Pol II in WT cells, because TL
function in controlling Pol II activity should be downstream of
promoter melting. Using permanganate footprinting to identify
regions of single-stranded DNA in the GAL1 and GAL10
promoters, Giardina and Lis observed strong permanganate
reactivity at greater than 60 basepairs (bp) upstream of the major
transcriptional start sites, indicating promoter melting far
upstream [89]. We reasoned that GAL1 should show far
upstream start site shifts in TL GOF mutants within this melted
region though it does not normally support productive start sites.
Indeed, we observed new start site usage more than 40 bp
upstream of the major GAL1 start sites in TL GOF mutants, and
a slight shift in starts sites downstream in TL LOF H1085Y
(Figure 6C)(Figure S7).
Discussion
The contributions of TL residues to the Pol II nucleotide
addition cycle (‘‘activity’’ for the purposes of this discussion) are
critical for transcription in vitro and in vivo. The catalytic
contribution of the TL has been proposed to function through
minimization of NTP dynamics within the Pol II active site, which
in turn could increase the probability of catalysis [90]. Our
biochemical experiments coupled with extensive genetic analyses
provide insight into the function of TL residues. We calculated an
approximate 6-fold suppression effect on elongation rate conferred
by the E1103G GOF substitution when it was combined with LOF
substitutions. We used this fold enhancement to infer the putative
defects of inviable TL LOF substitution mutants for which we
were unable to measure elongation rate directly. Assuming an
approximate 6-fold increase in rate contributed by E1103G to the
values of E1103G-suppressed inviable substitution elongation
rates, we infer 7–30 fold defects for N1082A, H1085A and
Q1078A single substitutions (Figure 4B). Examination of analo-
gous substitutions in E. coli or T. thermophilus RNAPs has revealed
large differences in the contribution of these residues to catalysis
with NTP substrates (4 and 6 fold for Eco R933A
SceN1082A and
H936A
SceH1085A, respectively [7] vs. 50 and 100 fold for Tth
R1239A
SceN1082A and H1242A
SceH1085A, respectively [5]). Our
results indicate that S. cerevisiae Pol II TL residues have
contributions intermediate to TL residues from different bacteria
and suggest that contributions of TL residues to activity cover a
range of values in homologous enzymes.
Our data also support a functional relationship between regions
adjacent to TL hinges, where the TL has been observed to deviate
from its fully folded, NTP-bound conformation in crystal
structures. These regions are the location of most of the strong
Spt
2 and MPA
s TL substitutions, as well as the strongest GOF
alleles tested. These results underscore the idea that the TL is
finely balanced between functional states or conformations, and
that the hinges are sensitive to changes that in some cases can
promote Pol II activity. These changes likely occur at the expense
of fidelity, as has been shown for E1103G [2,9]. Alteration of distal
TL residues (e.g. E1103, G1097D) conferred broad suppression on
the absence of MPA or low GTP because upstream transcriptional starts are terminated at a terminator element (stop sign) that can be bypassed by
utilization of downstream start sites. D. Primer extension analysis for downstream IMD2 start site usage in Pol II TL mutants in presence or absence of
20 mg/ml MPA (2 hours treatment). Numbers on right indicate position of RNA terminus relative to the A of the IMD2 ATG codon. Sequence ladder on
right is derived from the primer used in (E) and has been cross-referenced with the primer used here. E. Primer extension analysis for upstream IMD2
start site usage in Pol II TL mutants as in (D). Numbers on right indicate position of RNA terminus relative to the A of the IMD2 ATG codon. Sequence
ladder on right is derived from the same primer used. The examples in D and E are representative of at least three independent experiments.
doi:10.1371/journal.pgen.1002627.g005
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NIR function can be compensated by alteration in trigger loop
dynamics. Importantly, functions of TL NIR residues are not
completely bypassed, as activities of tested double mutants are
intermediate between the single mutants, and not all NIR mutants
are suppressible (Table 1, Text S1).
Functional distinctions between TL residues and genetic
epistasis between some residue combinations have been hinted
at in the case of residues analogous to Q1078 and N1082 in T.
thermophilus experiments [5](Text S1), but our combinatorial
genetic analyses reveal this more clearly (Figure 4). Examination
of different Pol II crystal structures shows the TL in a number of
Figure 6. Pol II TL contributes to start site selection at a number of genes. A. Primer extension analysis of RNA 59-ends at ADH1 in Pol II TL
mutants. Sequence ladder at left is derived from primer used in Figure 5E but has been cross-referenced with ADH1 primer used for primer extension
here. Numbers indicate positions of putative start sites in relation to the ADH1 ATG (A is +1). Right panel quantifies start site usage at ADH1 as
determined by primer extension with a radiolabeled oligo. Signals in each lane were divided into bins based on positions of start sites relative to
ADH1 ATG sequence (A is +1) and normalized to total signal per lane. WT start site fractions were subtracted from mutant start site fractions for
particular regions to determine the relative alteration in start site distribution in Pol II mutant strains. A negative value indicates that the mutant has
relatively lower usage for that particular group of start sites and a positive value indicates a relatively higher usage for that particular group of start
sites. Values shown are the average of at least four independent experiments +/2 standard deviation. B. Primer extension analysis of RNA 59-ends at
HIS4 and PMA1 in Pol II TL mutants. C. Primer extension analysis of RNA 59-ends at GAL1 in Pol II TL mutants. Cells are grown in medium lacking
raffinose and then GAL1 is induced by addition of galactose to 2% for two hours. Sequence ladder at left is derived from the same primer used for
primer extension. Numbers indicate positions of putative start sites in relation to the GAL1 ATG (A is +1).
doi:10.1371/journal.pgen.1002627.g006
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absence of matched NTP or NTP analog [1,13,67](Figure 7).
These structures suggest a TL folding pathway wherein N-
terminal TL residues that are proximal to the N-terminal TL
hinge (primarily Q1078), along with other active site residues (for
example, Rpb1 R446 and N479), are positioned essentially at all
times for NTP interaction. Biochemical experiments indicate that
these residues function in ribose 29- and 39-hydroxyl (OH)
recognition, with the 29-OH of course critical for selection of NTPs
over 29-dNTPs [1,5,91]. Upon matched NTP basepairing with the
DNA template, NTP interactions with R446, N479 and Q1078
may stabilize or begin to promote TL-folding in an N-terminal to
C-terminal fashion, where L1081 and N1082 next come into
position via N-terminal TL hinge movement. Supporting such a
step, in some Pol II crystal structures, these residues are observed
adjacent to a matched NTP basepairing with the template, but
without complete folding or stabilization of the TL (Figure 7). Our
genetic analyses suggest that Q1078 and N1082 (along with N479)
are functionally interdependent (see also Text S1). Following initial
hinge movement and TL folding, H1085 and the rest of the TL
loop tip must fold into the closed conformation, and genetic
analyses of H1085 substitutions suggest this step is distinguishable
from functions of other TL NIR residues. It is important to note
that we have not been able to evaluate contributions of residues
L1081 and R446 in our genetic system because all tested
substitutions in these residues were inviable and these substitutions
were generally not suppressed by E1103G (Table 1, Table S1,
Text S1).
The Relationship between MPA Sensitivity and Pol II
Elongation Defects
In vivo it has been observed that some Pol II mutants
constitutively express IMD2 in the absence of drug-induced
stimulation [18,47]. It is unclear whether this constitutive
expression represents a mutant-induced alteration in Pol II start
site specificity or a generic reduction of Pol II activity that mimics
a drug-induced nucleotide depleted state, which itself leads to
altered start site selection. We show here that an MPA-resistant
LOF TL allele caused constitutive IMD2 expression, and in other
work we found that this expression is likely a generic hallmark for
reduced Pol II activity (Braberg et al, in preparation), and not
necessarily due to a specific defect in initiation as previously
proposed [57]. These results support published models that IMD2
regulation is directly responsive to reduction in nucleotide levels as
reduction or increase in Pol II catalytic rates have opposing effects
on the ability of IMD2 to be induced. Our observations that
reduced Pol II activity does not correlate with sensitivity to MPA
suggest that generic Pol II catalytic defects do not confer sensitivity
to reduced nucleotide levels. Given the fact that LOF TL mutants
are highly likely to confer elongation defects in vivo, the absence of
MPA-sensitivity raises the question of whether reduction of GTP
levels sensitizes cells to generic elongation defects caused by any
transcription factor proposed to be acting through Pol II
elongation. MPA sensitivity of any transcription factor mutant
should not be used to infer presence or absence of an elongation
defect because actual nucleotide levels in different mutant strains
may vastly differ due to IMD2 transcriptional effects.
Model for Start Site Selection in Budding Yeast
The observation that TL mutants show polar effects on start site
selection in vivo correlating with in vitro catalytic defects suggests a
model for how Pol II activity may directly influence initiation.
Start site selection in S. cerevisiae is not restricted to a short window
a defined distance from the TATA box, but instead can take place
over a longer region downstream [92]. It has been proposed that
Pol II scans for sequences permissive for productive elongation
[89]. We propose that our mutants primarily affect the nucleotide
addition cycle and not some other step in initiation, therefore we
Figure 7. Model for stepwise function of TL residues in contributing to TL folding and function. A. Structural cartoon showing overlay of
TLs and Rpb1 N479 from a number of Pol II elongation complex/initial transcribing complex crystal structures with TLs in different states of folding/
NTP interaction. Matched GTP nucleotide (orange) and TL and N479 (magenta) are from PDP 2E2H [1], which shows TL in a closed conformation.
Partially folded TL and N479 (yellow) from PDB 4A3F [13], which contains a matched NTP analog (not shown) and short RNA (not shown). Related
structure to PDB 4A3F from PDB 4A3D [13], but without matched NTP analog is shown in gray. Partially folded TL from PDB 1R9T, containing a
mismatched NTP (not shown) is shown in pink. B. Same figure as in (A) but with GTP omitted. Certain residues are relatively closely positioned in all
structures overlaid (N479, Q1078), while other residues are observed stabilized in partially folded structures directly adjacent to the active site (L1081,
N1082). H1085 is observed positioned adjacent to the active site only upon complete folding/stabilization of the TL. Dashed oval indicates likely
location of TL NIR residues when in out conformation where the TL is either mobile or unfolded. This figure was created with Pymol [111].
doi:10.1371/journal.pgen.1002627.g007
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start sites are not normally utilized in WT cells, and that scanning
occurs subsequent to template melting, as has been proposed for
GAL genes [89]. Continuous RNA synthesis during the scanning
process does not appear to be required for scanning, as
experiments show that chain-terminating nucleotides do not
abrogate scanning in vitro [93,94]. In light of these results, models
for start site scanning in yeast that do not invoke transcription have
been proposed (i.e. [95], also reviewed in [96]). We show that
substitutions within the Pol II TL that have increased activity in
vitro shift start sites upstream at ADH1, HIS3, PMA1 and GAL1,
and those with reduced in vitro activity shift start sites downstream
at ADH1 and GAL1 (Figure 6 and Figure S8). To explain these
data, we invoke a new transcription-assisted model for start site
scanning (Figure 8). Inefficiently or apparently unused start sites
may allow undetected abortive but not productive initiation. Such
abortive transcription may support Pol II downstream transloca-
tion, providing an explanation how Pol II catalytic mutants alter
start site selection in a polar fashion, which is indicative of altered
scanning as described in the flux model proposed by the Brow lab
[97]. In the flux model, Pol II scanning from upstream to
downstream will utilize starts in a polar fashion, and a decrease in
usage of an upstream start will lead to increased usage of a
downstream start. In our model, upstream shifts in start sites are
due to increased Pol II catalytic activity, which in turn increases
the probability of normally abortive initiation events becoming
productive at the expense of downstream events. Conversely,
downstream shifts in start sites are due to decreased Pol II activity,
which increases the probability that abortive initiation will occur at
upstream positions at the expense of productive initiation from
those positions. Competition between abortive and productive
initiation may occur at key transitions for early elongation
complex stability [98], or by modulating stability of RNA:DNA
hybrid in early transcription complexes as suggested by recent
structural studies from the Kornberg lab [99] and the Cramer lab
[13]. These new structures demonstrated a role for a matched
NTP substrate in the Pol II active site in stabilization of short
nascent RNAs. As GOF Pol II TL alleles have been implicated in
extending the duration of substrate-bound complexes [9], these
GOF alleles may also stabilize early elongation complexes in
addition to increasing elongation rate. Any increase in the
probability of next nucleotide incorporation at the expense of
transcript release would lead to a net increase in productive
elongation and a net decrease in downstream scanning by our
model.
Previously described start site-altering mutants in Pol II general
factors and other Pol II subunits have activities that are entirely
consistent with this model. rpb9D shows upstream shifts in start
sites at ADH1 (and other genes) [77,79], inability to shift to
downstream IMD2 starts upon MPA treatment, and causes Pol II
to be superactive in vitro [85], similarly to superactive TL mutants
E1103G and G1097D. An allele of the TFIIF subunit-encoding
TFG1 gene causes upstream start site shifts in vivo while increasing
efficiency of Pol II initiation in an abortive initiation assay,
consistent with this allele conferring an increase in Pol II activity
[94]. This increase in Pol II activity may be due to a gain of
function in TFIIF or a loss of a negative function, under our
activity-dependent framework for interpreting start site defects.
Consistent with the latter, a recent in vitro study shows that TFIIF
can inhibit initiation at specific template positions on a modified
HIS4 template [100]. On some of the templates used in this study,
TFIIF inhibits transcription initiation from upstream positions,
consistent with polarity of most start site shifting mutants of TFIIF
subunits in vivo. A number of sua7 (TFIIB) alleles show downstream
shifts in start site selection [76,101,102], and in the case of the
highly studied E62K allele, this mutant causes a decrease in Pol II
transcription efficiency in vitro [103]. We provide a framework for
interpreting the relationship between start site selection changes
and the nature of alteration of the initiation process. Increasing or
decreasing efficiency of productive initiation from particular
nucleotide positions may relate to upstream or downstream shifts
in start site selection, which appear to correlate with increases or
Figure 8. Model for transcription-assisted start site scanning through abortive initiation. Cartoon showing predicted start site
distribution for an ADH1-like gene in WT cells (top) or alteration in distribution in the presence of LOF (middle) or GOF (bottom) Pol II TL mutants.
doi:10.1371/journal.pgen.1002627.g008
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strongly correlate with Pol II activity, their contribution to the
growth defects of Pol II TL mutants remains to be determined.
Materials and Methods
Genetic Analyses
To examine mutant polymerase alleles encoding substitutions
in the TL and elsewhere in Rpb1, we perform a plasmid shuffle
with rpb1 CEN LEU2 plasmids by assaying ability of rpb1D cells to
grow without an RPB1 CEN URA3 plasmid. This is accomplished
by treatment of cells with the drug 5-fluoroorotic acid (5-FOA,
Gold Biotechnology), which is toxic to Ura3
+ cells [104], thus
selecting cells containing solely an rpb1 CEN LEU2 plasmid so we
might assess the ability of mutant plasmids to complement the
essential function of RPB1. During the course of our experiments,
we identified a previously unreported polymorphism in our RPB1
plasmid encoding substitution of isoleucine at position 69 for the
threonine reported for this position in the Yeast Genome
Database (T69I). This substitution was tracked as far back as
the pRP112 subclone derived from an original RPO21 genomic
clone from the Young lab [105]. Our analyses indicate that this
substitution is phenotypically inert (Figure S8), yet all genetic data
shown are for plasmids with the Ile69 corrected to threonine
(I69T).
Yeast Strains, Plasmids, and Media
Yeast media are prepared in standard fashion as described in
[106] with minor alterations. Yeast extract (1%)(BD), peptone
(2%)(BD), dextrose (2%)(‘‘YPD’’) solid medium (2% bacto-agar,
BD) is supplemented with adenine (0.15 mM final) and tryptophan
(0.4 mM final)(Sigma-Aldrich). YP plates with alternate carbon
sources such as raffinose (2%, USB) or raffinose (2%) plus
galactose (1%, Sigma-Aldrich) also contain antimycin A (1 mg/ml,
Sigma-Aldrich). Minimal media plates are synthetic complete
(‘‘SC’’/‘‘Hopkins mix’’) with amino-acids dropped out as appro-
priate as described in [106] with minor alterations: per standard
batch formulation Adenine Hemisulfate was 2 g, Uracil was 2 g,
myo-inositol was 0.1 g, p-Aminobenzoic acid (PABA) was 0.2 g.
For studies with mycophenolic acid (MPA, Sigma-Aldrich), MPA
was added to minimal SC-Leucine medium at 20 mg/ml from a
10 mg/ml stock in ethanol. Construction of mutants is described
in Text S1. Yeast strain genotypes, numbers and plasmid
descriptions are found in Tables S1 and S2.
Pol II Purification and In Vitro Transcription Assays
Pol II enzymes were purified from yeast strains expressing
mutant rpb1 genes from a low copy plasmid from the endogenous
RPO21 promoter via a tandem-affinity tag (TAP) on Rpb3, in a
procedure derived from [107] and as described in [2]. All mutant
enzymes are Rpb1 I69 variants, except H1085Q/E1103G,
F1086S/E1103G and Q1078A/E1103G, which are T69 variants.
Transcription reactions of Pol II elongation complexes formed on
nucleic acid scaffolds follow the approach described by Komissar-
ova et al [108], and are performed as in [2] with the following
modifications: for some experiments, amounts of all nucleic acids
were reduced to 1/10
th the amount stated in [2] (to 30 pmol from
300 pmol, etc.)(Text S1). Reactions were separated on 13.5%
acrylamide-bisacrylamide gels (19:1 ratio) containing 16TBE and
7 M urea and quantitated as previously described [2].
Primer Extension and Northern Blotting Analysis
Total yeast RNA was purified as described [109]. Primer
extension analysis was performed exactly as described (http://labs.
fhcrc.org/hahn/Methods/mol_bio_meth/primer_ext.html) [110]
with the following modifications. Total RNA used was 30 mg, and
in the case of more dilute RNA samples, volumes of reactions were
increased by 50% to accommodate greater volume of sample.
Reverse transcriptase (RT) was M-MLV RT from either Life
Technologies or Fermentas. RT synthesis reactions were supple-
mented with 1 ml RNAse Inhibitor (Fermentas). Extension
products were separated on either 7% or 10% acrylamide-
bisacrylamide gels (19:1 ratio) containing 16TBE and 7 M Urea.
Northern blotting was performed essentially as described in
manual for GeneScreen hybridization membranes (Perkin-Elmer)
with the following modifications. RNA samples (20 mg) were
prepared in NorthernMax loading buffer (Ambion/AB). Prehy-
bridization solution did not contain SSPE or SSC buffers, but
contained 56Denhardt’s solution, 50 mM Tris-HCl pH 7.5, 1 M
NaCl, 0.1% sodium pyrophosphate, 0.1% SDS instead of 1%,
10% Dextran Sulfate, 50% formamide, and 500 mg/ml sheared/
denatured salmon sperm DNA. Probes for northern blots were
radiolabeled using a-
32P-dATP by random priming using the
Decaprime II kit (Ambion) according to manufacturer’s instruc-
tions. Blots were washed at twice for 10 minutes each wash at
42uC with 26SSC, 0.5% SDS, then twice at 67uC with 56SSC,
0.5% SDS for 30 minutes each wash, then twice in 0.26SSC for
30 minutes each wash at room temperature. Primer extension gels
and northern blots were visualized by phosphorimaging (GE
Healthcare or Bio-Rad) and quantified using ImageQuant 5.0
(GE) or Quantity One (Bio-Rad) software, with data exported to
Microsoft Excel for management. Oligo sequences for site-directed
mutagenesis, primer extension analysis, amplification of DNA for
Northern blotting and in vitro transcription are available upon
request.
Supporting Information
Figure S1 In vivo transcriptional phenotypes utilized in this
study. A. The Spt
2 phenotype utilized in this work relates to
suppression of a Ty1 delta (h) element insertion into the 59 end of
the LYS2 coding region creating the lys2-128h allele [59]. This
insertion renders WT cells Lys
2 (top) as they are only able to
express a short non-functional transcript (black arrow), while
mutation of a number of factors allows transcription of LYS2 from
a cryptic promoter (red arrow, bottom), most likely somewhere
within the h insertion, allowing the cells to become Lys
+. B. The
galactose toxicity phenotype utilized here relates to transcriptional
interference between GAL10 transcription and GAL7 transcription
caused by compromise of GAL10 39-end formation through
deletion of the major polyadenylation signal (gal10D56) and
subsequent interference with GAL7 initiation (black arrows)
[60,61,112]. Decrease in GAL7 transcription allows the buildup
of a toxic metabolite normally metabolized by Gal7p, thus
presence of galactose in the medium becomes toxic under
conditions where other GAL genes are expressed. Mutations in a
number of factors that enhance GAL10 39-end formation, enhance
termination downstream of GAL10, or increase GAL7 transcription
can suppress this toxicity (red arrows).
(TIF)
Figure S2 Genetic analyses of Pol II TL single substitution
mutants combined with E1103G or G1097D substitutions
distinguish between different classes of Pol II mutant and show
extensive suppressive relationships. A. 10-fold serial dilutions of
saturated cultures for a number of Pol II TL substitutions
combined with E1103G plated on different media as in Figure 1,
with single mutant panels from Figure 1 shown for comparison
purposes. B. 10-fold serial dilutions of saturated cultures for a
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plated on different media as in Figure 1.
(TIF)
Figure S3 Additional Pol II TL single substitution and multiple
substitution mutants. 10-fold serial dilutions of saturated cultures
of Pol II TL mutant strains plated on different media. Also note
that the multiply substituted Q1078S/N1082A/H1085Y/E1103G
mutant is viable but confers a strong growth defect. When
combined with an A1076V substitution, previously identified as
sit1-8G (as a double mutant with rpb1-N479Y conferring a
phenotype reminiscent of the Spt
2 phenotype) [22], we observed
that A1076V suppressed growth defects of Q1078S/N1082A/
H1085Y/E1103G, and that it also confers viability to Q1078A/
N1082A/H1085Y/E1103G.
(TIF)
Figure S4 Quantification of elongation rates in Pol II mutants.
Run-off transcription as a fraction of total transcription is
determined and plotted versus reaction time for specified Pol II
mutants. Multiple lines per graph indicate data from time courses
generated from separate individual reactions. A. WT I69. B. WT
T69. C. N1082S. D. H1085Q. E. L1101S. F. E1103G. G.
F1086S/E1103G. H. H1085Q/E1103G. I. H1085Y/E1103G. J.
N1082A/E1103G. K. H1085A/E1103G. L. Q1078A/E1103G.
M. G1097D with standard NTP concentrations. N. G1097D with
high NTP concentrations (MgCl2 raised to 10 mM from 5 mM).
(TIF)
Figure S5 Quantification of elongation rates in Pol II mutants.
Rates determined from Figure S4 for each NTP concentration are
plotted versus NTP concentration and curve fitted by non-linear
regression. A. WT Pol II enzymes. B. Single mutant Pol II
enzymes. C. Double mutant Pol II enzymes. D. G1097D with
standard NTP concentrations. E. G1097D with high NTP
concentrations (MgCl2 raised to 10 mM from 5 mM).
(TIF)
Figure S6 Western blotting for Rpb1 and Rpb3-TAP from Pol
II variants. A. Western blotting for Rpb1 expression levels from
WT and rpb1 mutant yeast strains using an antibody to the N-
terminus of Rpb1 (Text S1). Because our strains contain Rpb3-
TAP, the protein A tag on Rpb3-TAP was also recognized by
either the primary or secondary antibodies used. Blotting for Pgk1
was used to confirm equal loading of lanes (bottom panels). Blots
shown are representative of three independent experiments. B.
Quantification of Rpb1/Pgk1 ratio from three independent
experiments. Error bars indicate +/2 standard deviation of the
mean. The anti-Rpb1 antibody has a high background, and
subtraction of this background caused standard deviations to
generally increase, so both background subtracted and unsub-
tracted quantifications are shown.
(TIF)
Figure S7 Quantification of start site distribution at GAL1 in Pol
II mutants. Start site usage at GAL1 as determined by primer
extension with radiolabeled oligo was divided into bins based on
radioactive signal at positions of start sites relative to GAL1 ATG
sequence (A is +1) and normalized to total signal per lane. WT
start site fractions were subtracted from mutant start site fractions
for particular regions to determine the relative alteration in start
site distribution in Pol II mutant strains. A negative value indicates
that the mutant has relatively lower usage for that particular group
of start sites and a positive value indicates a relatively higher usage
for that particular group of start sites. Values shown are the
average of three independent experiments +/2 standard devia-
tion.
(TIF)
Figure S8 No effect of Rpb1 I69 substitution on in vivo
phenotypes. 10-fold serial dilutions of yeast strains expressing
T69 or I69 variants of Rpb1 as the sole source of Rpb1 were
spotted onto various media to determine phenotypes. Results
indicate that I69 is phenotypically inert.
(TIF)
Table S1 rpb1 mutant plasmids used in genetic analyses of the
Pol II TL.
(DOCX)
Table S2 Strain genotypes for yeast used in this study.
(DOCX)
Text S1 Description of plasmids, yeast strains, supporting
discussion of genetic analyses of Pol II TL residues, and supporting
methods.
(DOCX)
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